Journal of Diagnostics Concepts & Practice >

2023 , Vol. 22 >Issue 04: 407 - 411

DOI: https://doi.org/10.16150/j.1671-2870.2023.04.013

Review articles

Advancements in M protein interference in the clinical laboratory detection

Expand
  • 1. Department of Medical Laboratory Center, The First People's Hospital of Taicang, Taicang Affiliated Hospital of Soochow University, Taicang 215400
    2a. Department of Rheumatology and Immunology, 2b. Department of Laboratory Medicine, Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 200025

Received date: 2023-06-25

  Online published: 2023-12-18

Fold

Abstract

M protein is a unique immunoglobulin type that often affects the laboratory results of certain blood tests. The M protein interference exits in the pre-analytical, analytical and post-analytical process, seriously affecting the accuracy of tests. For example, high concentrations of M protein in serum creatinine, uric acid, lipoprotein, total protein, bilirubin, blood glucose, phosphorus, hemoglobin, glycosylated albumin can cause false high or false low results. The abnormal presence of M protein in 25-OH vitamin D, thyroid-stimulating hormone, c-reactive protein, vancomycin, gentamicin and sodium valproate concentrations interferes with the actual detection results. Solutions to the above problems include diluting serum or removing protein before testing, using protein stabilizers during testing or optimizing reaction conditions. Furthermore, in clinical practice, hidden M protein can be uncovered, and effective detection prior to the onset of disease can open new avenues for disease management and prognosis.

Key words： M protein; Interference; Laboratory test

Cite this article

PAN Xiaoyuan, SHI Hui, CAO Jijun, SHI Xinming, SHI Ce . Advancements in M protein interference in the clinical laboratory detection[J]. Journal of Diagnostics Concepts & Practice, 2023 , 22(04) : 407 -411 . DOI: 10.16150/j.1671-2870.2023.04.013

References

[1] COWAN A J, GREEN D J, KWOK M, et al. Diagnosis and management of multiple myeloma: a review[J]. JAMA, 2022, 327(5):464-477.
[2] LANDGREN O. Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events[J]. Hematology Am Soc Hematol Educ Program, 2021, 2021(1):662-672.
[3] MASE H, HAMANO N, MIZUHARA R, et al. Falsely Elevated Serum Creatinine Associated With IgM Paraproteinemia[J]. Kidney Int Rep, 2019, 5(3):377-381.
[4] SHIMAMURA Y, MAEDA T, OGAWA Y, et al. Unusual manifestation of monoclonal gammopathy of undetermined significance: a false serum creatinine elevation[J]. CEN Case Rep, 2020, 9(2):109-113.
[5] NAUTI A, BARASSI A, MERLINI G, et al. Paraprotein interference in an assay of conjugated bilirubin[J]. Clin Chem, 2005, 51(6):1076-1077.
[6] LANGMAN L J, ALLEN L C, ROMASCHIN A D. Interference of IgM paraproteins in the Olympus AU800 uric acid assay[J]. Clin Biochem, 1998, 31(7):517-521.
[7] YILMAZ N S, SEN B, GULBAHAR O. Contribution of the laboratory to a diagnosis process by sequential reflective testing: Paraprotein interference on a direct bilirubin assay[J]. Biochem Med (Zagreb), 2021, 31(2):020801.
[8] SONG L, TONG K H, CHIN C D. Gelation of monoclonal protein was the cause of interference with a total bilirubin assay[J]. J Appl Lab Med, 2019, 3(6):1054-1058.
[9] MELVILLE A, THOMAS S D C. Paraprotein interference of automated total bilirubin measurement[J]. Pathology, 2022, 54(3):365-367.
[10] TSAI L Y, TSAI S M, LEE S C, et al. Falsely low LDL-cholesterol concentrations and artifactual undetectable HDL-cholesterol measured by direct methods in a patient with monoclonal paraprotein[J]. Clin Chim Acta, 2005, 358(1-2):192-195.
[11] MONK C, WALLAGE M, WASSELL J, et al. A monoclonal protein identified by an anomalous lipaemia index[J]. Ann Clin Biochem, 2009, 46(Pt 3):250-252.
[12] TICHY M, FRIEDECKY B, BUDINA M, et al. Interfe-rence of IgM-lambda paraprotein with biuret-type assay for total serum protein quantification[J]. Clin Chem Lab Med, 2009, 47(2):235-236.
[13] KRITMETAPAK K, DUMRONGSUKIT S, JINCHAI J, et al. Pseudohyperphosphatemia in a patient with relapsed multiple myeloma after bone marrow transplantation: a case report[J]. Clin Case Rep, 2019, 7(7):1426-1429.
[14] KIKI I, GUNDOGDU M, KAYA H. Spuriously high phosphate level which is promptly resolved after plasmaphe-resis in a patient with multiple myeloma[J]. Transfus Apher Sci, 2007, 37(2):157-159.
[15] BOSSARD V, SAUVAGEON Y, FRAISSINET F, et al. False paraprotein-induced hypoglycemia in the measurement of glucose by the hexokinase method[J]. Ann Biol Clin (Paris), 2019, 77(4):439-445.
[16] KURAMOTO N, WAKAHARA T, TAMAGAWA Y, et al. A case of monoclonal gammopathy of undetermined significance with abnormal low levels of plasma glycated albumin by M protein[J]. Clin Chim Acta, 2018, 487:337-340.
[17] ROBERTS W L, FONTENOT J D, LEHMAN C M. Overe-stimation of hemoglobin in a patient with an IgA-kappa monoclonal gammopathy[J]. Arch Pathol Lab Med, 2000, 124(4):616-618.
[18] ONG M W, SALOTA R, REEMAN T, et al. Artefactual 25-OH vitamin D concentration in multiple myeloma[J]. Ann Clin Biochem, 2017, 54(6):716-720.
[19] HAGER H B, BOLSTAD N, WARREN D J, et al. Falsely markedly elevated 25-hydroxyvitamin D in patients with monoclonal gammopathies[J]. Clin Chem Lab Med, 2020, 59(4):663-669.
[20] LUZZI V I, SCOTT M G, GRONOWSKI A M. Negative thyrotropin assay interference associated with an IgGkappa paraprotein[J]. Clin Chem, 2003, 49(4):709-710.
[21] YU A, PIRA U. False increase in serum C-reactive protein caused by monoclonal IgM-lambda: a case report[J]. Clin Chem Lab Med, 2001, 39(10):983-987.
[22] LEGATT D F, BLAKNEY G B, HIGGINS T N, et al. The effect of paraproteins and rheumatoid factor on four commercial immunoassays for vancomycin: implications for laboratorians and other health care professionals[J]. Ther Drug Monit, 2012, 34(3):306-311.
[23] DIMESKI G, BASSETT K, BROWN N. Paraprotein interference with turbidimetric gentamicin assay[J]. Biochem Med (Zagreb), 2015, 25(1):117-124.
[24] FORNI G L, PINTO V, MUSSO M, et al. Transferrin-immune complex disease: a potentially overlooked gammopathy mediated by IgM and IgG[J]. Am J Hematol, 2013, 88(12):1045-1049.
[25] KHANT M, FLORKOWSKI C, LIVESEY J, et al. Insulin autoimmune syndrome due to IgG kappa paraprotein[J]. Pathology, 2004, 36(1):86-87.
[26] WU X Y, YIN Y F, TENG J L, et al. IgMk paraprotein from gammopathy patient can bind to cardiolipin and interfere with coagulation assay: a case report[J]. BMC Immunol, 2017, 18(1):32.
[27] VON LANDENBERG P, SCH?LMERICH J, ANDREESEN R, et al. A case of Waldenstroem's disease with a monoclonal IgM antiphospholipid antibody[J]. Rheumatol Int, 2002, 22(3):129-131.
[28] DJUNIC I, ELEZOVIC I, ILIC V, et al. The effect of paraprotein on platelet aggregation[J]. J Clin Lab Anal, 2014, 28(2):141-146.
[29] DJUNIC I, ELEZOVIC I, VUCIC M, et al. Specific bin-ding of paraprotein to platelet receptors as a cause of platelet dysfunction in monoclonal gammopathies[J]. Acta Haematol, 2013, 130(2):101-107.
[30] RANI P, KUMAR T, KUMAR S, et al. IgA monoclonal gammopathy with pseudohyperphosphatemia[J]. Indian J Clin Biochem, 2022, 37(1):119-123.
Options
Outlines

/

〈 〉